Dilon inks sales pact with PenRad

AuntMinnie.com staff writers
Aug 29, 2011

Breast-specific gamma imaging developer Dilon Diagnostics has signed a three-year sales agreement with mammography information systems developer PenRad Technologies.

Under the terms of the pact, Dilon's portfolio now will include the PenRad mammography information system (MIS) and also Volpara, a quantitative breast density assessment tool designed to convert a qualitative breast x-ray image into quantitative data.
Latest in Breast
Mammogram Breast 400
Ikonopedia updates breast reporting platform for BI-RADS v2025
September 17, 2026
Covid 19 Map 400
UH-WBI use increased during COVID-19 pandemic
September 11, 2026
Mammo Adobe Gorodenkoff
Neighborhood deprivation tied to lower breast cancer screening
September 2, 2026
Breast Cancer
Mammotome expands production of breast biopsy system
September 1, 2026
Related Stories
2011 08 24 15 39 30 522 2011 08 25 Shutter Speed Breast Mri
MRI
Shutter-speed MRI more accurate for breast cancer diagnosis
2011 08 09 11 56 38 249 Stanford Breast Coil Image 02 Thumb
MRI
Stanford group shrinks MRI coil for better breast imaging
2011 07 29 08 17 13 510 2011 07 28 Bmj Thumb
Breast
Debate over breast screening to intensify after new BMJ study
2011 07 06 16 04 57 96 Li Mri Breast Thumb
MRI
CE-MRI predicts survival in breast cancer patients after chemo
More in Breast
Ikonopedia updates breast reporting platform for BI-RADS v2025
By AuntMinnie.com staff writers
The company's structured breast imaging reporting platform now includes updated terminology from BI-RADS v2025.
September 17, 2026
Mammogram Breast 400
UH-WBI use increased during COVID-19 pandemic
By Amerigo Allegretto
The use of ultra-hypofractionated whole-breast irradiation (UH-WBI) increased by five times during the pandemic.
September 11, 2026
Covid 19 Map 400
Neighborhood deprivation tied to lower breast cancer screening
By Amerigo Allegretto
Women residing in neighborhoods with high deprivation have lower odds of getting their mammograms.
September 2, 2026
Mammo Adobe Gorodenkoff
Mammotome expands production of breast biopsy system
By AuntMinnie.com staff writers
The company said it's increasing production to help address a U.S. shortage of stereotactic breast biopsy needles.
September 1, 2026
Breast Cancer
CureMetrix secures FDA clearance for cmAngio 2.0
By AuntMinnie.com staff writers
The update introduces BAC quantification, age-based BAC percentile scoring compared against a reference library of more than 170,000 studies.
August 17, 2026
Bac
Longitudinal DBT could help improve long-term cancer risk prediction
By Amerigo Allegretto
A longitudinal DBT model outperformed other models based on mammography and clinical factors in predicting five-year cancer risk.
August 13, 2026
Breast Dbt 400
AI tools may not meet breast radiologists' expectations in practice
By Amerigo Allegretto
AI tools in breast imaging may have more modest clinical impact on recall and biopsy rates.
August 12, 2026
Breast Mammo Computer 400 (3)
NME breast lesions have high malignancy rate on MRI-guided biopsy
By Amerigo Allegretto
Biopsies from women with a known ipsilateral malignancy have a higher frequency of breast cancer.
August 10, 2026
Mri Breast 400
DBT-based foundational model classifies breast density
By Amerigo Allegretto
DBT-DINO showed strong performance in classifying breast density from DBT images.
August 4, 2026
(A) Free-response receiver operating characteristic (FROC) curve for DBT-DINO and DINOv2 (Meta AI) on the detection task. DINOv2 achieved higher sensitivity than DBT-DINO across most false-positive thresholds. (B) Detection rates of DBT-DINO and DINOv2 for lesions that were ultimately found to be benign (n = 70) and lesions that were found to be cancerous (n = 66). Error bars represent 95% CIs estimated via patient-level bootstrapping with 1000 repetitions. Both models showed similar detection rates for cancerous lesions, whereas DINOv2 detected more benign lesions than DBT-DINO. (C) Example bounding box predictions for DBT-DINO and DINOv2 on the detection test set. Each image is a single two-dimensional section from a three-dimensional digital breast tomosynthesis volume; the first column shows a mediolateral oblique view, and the second and third columns show craniocaudal views. Both models struggled to detect very small lesions, such as the 3-mm-diameter lesion shown in the first column. FP = false positive.
RadSite publishes clinical coverage guideline for breast CBCT imaging
By AuntMinnie.com staff writers
The guide outlines how breast CBCT should be used when conventional imaging approaches are inconclusive or inaccessible.
July 30, 2026
Rad Site
CEM finds breast cancer at baseline, incidence screening
By Amerigo Allegretto
Incidence screening with CEM maintains high performance and may offer more benefits over baseline CEM screening.
July 28, 2026
Images in a 70-year-old asymptomatic woman with a prior excisional biopsy in the left breast yielding lobular carcinoma in situ 3 years earlier. Screening contrast-enhanced mammography (CEM) was performed, which was considered a prevalence screen as the woman had no prior breast MRI in the past 3 years and no prior CEM. (A) Low-energy (26–30 kVp) mediolateral oblique (MLO) and (B) craniocaudal (CC) views show surgical clips but no abnormality. (C) Recombined MLO and (D) CC images show an enhancing mass in the medial left breast (arrows). Biopsy revealed invasive lobular carcinoma. Size was 0.2 cm; tumor grade II/III; negative lymph nodes; and estrogen receptor–positive, progesterone receptor–positive, and human epidermal growth factor receptor 2–negative.
Women's Imaging MinnieCast, Episode 13: Partial breast irradiation in the spotlight
By Amerigo Allegretto
Two committee members for ASTRO's PBI guidelines share insights about this breast cancer treatment option.
July 17, 2026
Minnie Cast Thumbnail (15)
Page 1 of 584
Next Page